Key Takeaways
- DSO sale price is driven by a multiple applied to adjusted EBITDA. Every major metric raises or lowers that multiple.
- Key financial metrics can include normalized EBITDA, annual collections above the $1.5M threshold, overhead percentage, and collections efficiency.
- Operational metrics such as owner dependence, provider mix, hygiene production, and recall compliance can shape buyer risk assessment and valuation.
- Payer mix, specialty mix, and geographic fit can affect both the multiple and deal structure, with fee-for-service and strategic-location practices often earning premiums.
- McLerran & Associates helps practice owners improve these metrics and navigate the sale process to pursue stronger outcomes.
Talk with McLerran & Associates about your practice’s current metrics.
How To Move The Financial Metrics That Set Your Baseline
Adjusted EBITDA
Adjusted EBITDA is normalized cash flow after add-backs. These add-backs can include owner compensation above a market-rate associate salary, personal expenses run through the practice, above-market related-party rent, and one-time or non-recurring costs. Buyers apply the multiple to this number, so each dollar added or removed is multiplied at closing.
If an owner pays themselves $600,000 while an equivalent associate would cost $280,000, the $320,000 difference flows into normalized EBITDA. Each adjustment directly and proportionally affects the transaction price. The pre-sale work is clear: separate personal expenses from the practice P&L so add-backs are visible, document each add-back with payroll records and invoices so a buyer can verify it, and normalize owner compensation to a defensible market-rate associate salary so the adjusted EBITDA figure holds up under review.
- What the buyer’s QoE team will challenge: Unsupported add-backs, recurring costs presented as one-time, and owner compensation set below a sustainable post-close level. As noted later in this article, the vast majority of lower-middle-market dental deals see a post-LOI adjustment, and the re-trade often begins with contested add-backs.
Annual Collections And The $1.5M Threshold
Trailing collections establish the revenue base buyers use as a reasonableness check against EBITDA. Scale can matter because it unlocks platform economics. DSOs generally look for practices with a minimum of $1.5 million in annual gross revenue, and practices approaching or exceeding that threshold often attract broader institutional interest and stronger pricing.
- What moves it: Durable same-store growth over 24 to 36 months. Buyers usually give more weight to same-location production growth than to total revenue growth driven by new locations.
- What the QoE team will challenge: Production that does not convert to collections and growth that does not come from the same store.
Overhead Percentage
Overhead percentage is total operating expenses divided by collections. A healthy overhead percentage for a U.S. general dentist solo practice in 2026 is roughly 60% to 65% in urban and suburban markets. Overhead above that range compresses EBITDA margin and therefore valuation. For a $1.2 million practice running at 60% overhead, pushing overhead to 65% drops EBITDA by $60,000, and at a 5x multiple, the sale price falls $300,000.
The cost lines DSOs scrutinize most are staff compensation, supplies, lab, and facility. Staffing and lease normalization typically take 12 to 24 months. Marketing and supply normalization often take 6 to 12 months. Buyers underwrite on trailing-twelve-months performance, so a turnaround usually must begin about 24 months before listing to appear fully in the financials at sale.
- What the QoE team will challenge: Margins that reflect underpaid labor, deferred hiring, or deferred equipment spend instead of durable operating improvement.
Revenue Growth Trend And Collections Efficiency / AR Aging
Durable growth and clean receivables can support the buyer’s forward view of earnings. DSO buyers compare production, adjustments, collections, write-offs, AR aging, and cash receipts to see whether revenue reliably converts into cash. A practice can show attractive production but still face valuation pressure if collections are slow, insurance denials are elevated, or AR includes stale balances that are unlikely to be collected.
- What moves it: Tighten collections realization, resolve stale AR and patient credits, and document write-off patterns by payer so revenue quality is clear.
- What the QoE team will challenge: A widening gap between production and collections, slow AR, and unexplained write-off changes.
How To Move The Operational Metrics That Determine Your Multiple
Financial metrics set your baseline. Operational metrics shape how much risk a buyer assigns to that baseline and therefore the multiple they apply.
Owner Dependence And Provider Mix
Owner dependence, meaning the share of production tied to the founding dentist, can be one of the most consequential metrics in a DSO transaction. DSO buyers model a post-close revenue deterioration scenario if the founding dentist generates more than 40% of total collected revenue, and they often require that no single provider represent more than 35% of total collected production.
As more production concentrates in the selling dentist, buyers worry more about transition. They review doctor-level production, associate contracts, provider tenure, hygienist retention, patient relationships, and the seller’s willingness to remain involved. In practice, this concern can show up as a lower multiple, a larger earnout, or a longer employment commitment with a smaller portion of value paid at close.
- What moves it: Hire and season an associate, distribute new-patient exams to associates, and build associate production that is visible in trailing 24-month practice management system (PMS) data. A practice where associate production grew from 20% to 45% of collections over 3 years tells a very different story than one where the founding dentist still handles every crown and implant.
The Interaction To Understand: Hiring an associate lowers owner dependence but can temporarily compress EBITDA margin. The net effect on price depends on whether the multiple expansion from lower transition risk outweighs the near-term margin dip. Adding even one producing associate can move an owner-dependent practice up a full turn of EBITDA multiple. The timing matters because the associate’s production needs to be visible in trailing financials before you go to market.
- What the QoE team will challenge: Associate retention risk, unwritten or unenforceable associate agreements, and production history that does not show a real transfer of patient relationships.
Hygiene Production And Recall
Hygiene production as a share of total collections is a recurring-revenue signal. Buyers treat it as evidence of patient retention and a healthier restorative pipeline. DSO underwriting often benchmarks hygiene production at 28% to 35% of total practice production. Below 25% can suggest hygiene capacity constraints, high attrition in the active patient base, or over-indexing to new patient acquisition at the expense of retention. On recall, benchmarks often include a pre-booking rate above 85% and active patient recall compliance above 70%.
- What moves it: Strong recall protocols, hygiene capacity expansion, consistent pre-booking, and reactivation reporting.
- What the QoE team will challenge: Hygiene below 25% of production, weak recall, and open hygiene capacity that the practice cannot fill.
How To Move The Payer, Specialty, And Strategic-Fit Metrics
Payer Mix
Payer mix, meaning the balance of fee-for-service, PPO, and government payer revenue, can affect both the applicable multiple and the deal structure. Payer mix drove observed intra-band variance of roughly 1.0 to 2.0 turns in dental practice multiples from 2024 through Q2 2026, with fee-for-service dominant practices trading at the top of published ranges and Medicaid-heavy practices generally trading at the bottom.
Heavy government payer concentration can suppress the applicable multiple by 10% to 30% relative to a comparable commercial insurance or fee-for-service practice in the same market. Practices with government payer concentration above 25% of total collections are often less attractive to institutional buyers.
- What moves it: Shift mix where clinically and commercially feasible, and document reimbursement rates and write-offs by payer.
- What the QoE team will challenge: Government payer concentration above roughly 25% of collections and write-off percentages that hide revenue-quality gaps.
Specialty Mix
The practice’s clinical specialty and procedure mix can influence which buyers compete and at what multiple tier. Oral and maxillofacial surgery and orthodontics traded roughly 1.0 to 3.0 turns above equivalent-sized general practice on adjusted EBITDA in 2024 through Q2 2026, while general dentistry continues to earn strong valuations. Specialty revenue that is concentrated in the selling dentist or dependent on a narrow referral source is often treated as risk rather than premium value.
- What moves it: Bring high-value procedures in-house where clinically appropriate, and document that specialty revenue is not concentrated in the selling dentist or a single referral source.
- What the QoE team will challenge: Specialty revenue that depends heavily on the founder personally or on one referrer.
Geographic And Strategic Fit
Geography and strategic fit can change how much a specific buyer is willing to pay. A practice that adds density, recruiting infrastructure, or specialty coverage to a buyer’s existing regional footprint can be worth more to that buyer than to one without local operating support. That extra value is buyer-specific strategic value rather than a universal market premium.
- What moves it: Identify which buyers see strategic value beyond the standalone financials. A structured, competitive process among multiple vetted buyers often surfaces better pricing than a one-to-one negotiation with a single DSO.
How To Sequence Your Pre-Sale Fixes In The 12–24 Months Before Affiliation
Not every metric deserves equal attention at every practice size. Smaller premier practices can often prioritize owner dependence and hygiene first. Larger practices approaching platform scale can focus on overhead, reporting quality, and management depth. Specialists can focus on referral portability and provider depth.
Across practice sizes, the first moves usually look similar:
- Separate owner compensation to market rate in the P&L
- Begin distributing new-patient exams to associates
- Pull trailing 24-month same-store production by provider from your PMS
- Conduct an internal billing audit
Metrics interact in ways that matter. Adding an associate, for example, reduces owner dependence but temporarily lowers EBITDA margin. Similarly, trimming overhead raises EBITDA but may require 12 to 24 months to appear in trailing financials. Shifting payer mix improves the multiple but takes time to show in collections. The goal is to understand the net effect on sale price, which is where a dental-only sell-side advisor can add value before you ever speak to a buyer.
Discuss your 12–24 month plan with a McLerran & Associates advisor.
What A DSO’s Quality-Of-Earnings Team Will Challenge And How To Prepare
Roughly 85% of lower-middle-market dental deals see a post-LOI price adjustment during the quality-of-earnings audit, with projected purchase price reductions of 28% to 40% across some roll-up portfolios. The re-trade almost always begins after the letter of intent (LOI) is signed and exclusivity is granted, which is the moment when the seller has the least leverage.
The QoE team will often focus on:
- Unsupported add-backs
- Owner compensation normalization
- Related-party rent
- One-time costs that look recurring
- Clinical documentation patterns and CDT code compliance
Pre-empting these challenges requires a defensible EBITDA bridge built before the process begins. That bridge should include provider-level and location-level economics, patient, hygiene, and collections data, and organized employment, lease, equipment, and compliance files. Once a buyer discovers an issue during diligence, the seller usually negotiates from a defensive position.
This preparation is a core part of McLerran & Associates’ process. The firm’s CPA-led, diligence-grade EBITDA analysis helps control the narrative around the owner’s profitability so the agreed value has a better chance of holding under buyer scrutiny. McLerran also reminds buyers, in a professional way, that other vetted bidders remain available if a buyer attempts to trade the deal down after the LOI.
Why DSO Valuation Metrics Differ From Private-Buyer Metrics
DSO deals typically price on a multiple of adjusted EBITDA. Doctor-to-doctor deals are often priced as a percentage of revenue or a multiple of net cash flow using Seller’s Discretionary Earnings (SDE). SDE adds back the owner-dentist’s full compensation instead of replacing it with a market-rate associate salary. A dental practice might show $400,000 in SDE but only $200,000 in normalized EBITDA. That gap represents the value of the owner’s own labor and is a frequent source of confusion in dental valuations. Comparing a DSO offer to a private-buyer offer without reconciling the earnings metric can produce a misleading picture.
Because McLerran & Associates regularly works in both private-buyer and DSO markets, the firm can prepare a side-by-side valuation that quantifies the practice’s worth in each path. This approach helps the owner choose a path with clearer information.
The table below summarizes how the two pricing bases differ and what each requires the seller to prepare.
| Pricing Basis | Typical Metric | What Drives The Number | What The Seller Should Prepare |
|---|---|---|---|
| DSO / Private Equity | Multiple of adjusted EBITDA. EBITDA usually anchors the most serious valuation discussion. | Normalized cash flow after owner compensation replacement, add-backs, and durability adjustments. Collections serve as a reasonableness check. | CPA-led EBITDA bridge with documented add-backs; provider-level production; hygiene, recall, and payer-mix reports; organized diligence files. |
| Doctor-To-Doctor (Private Buyer) | Percentage of annual collections or multiple of Seller’s Discretionary Earnings (SDE), which adds back the owner-dentist’s full compensation. | Direct cash flow, debt service coverage, payer mix, equipment condition, lease stability, and patient retention. | Clean trailing financials; active patient and recall data; assignable lease; equipment condition documentation; seller transition plan. |
Market Context: Post-Covid DSO Capital Cycle And Deal Structures
Large DSO valuation multiples have compressed to roughly 9 to 10 times EBITDA, down from historical peaks of 13 to 16 times in 2019 to 2021. Smaller dental practices have reverted to more traditional valuation ranges, reflecting a post-COVID normalization from peak-cycle pricing. Multiples have moderated, yet demand for premier, Class A assets remains strong.
Deal structures have also shifted. Most dental practice transactions divide total consideration into three components: cash at closing, rollover equity, and earnout payments. Buyers have increasingly used structures where a significant portion of consideration is deferred or equity-based. Up to roughly 40% of a DSO deal can be paid in equity instead of cash, held at either the joint-venture level or the holding-company level.
Rollover equity allows sellers to retain an ownership interest in the acquiring platform and participate in a potential second liquidity event. Its true value depends on governance rights, dilution protections, capital structure, and the timing and terms of any future exit. Equity functions like an investment and benefits from the same level of scrutiny.
Platform PE buyers typically require practices with $3 million or more in EBITDA, with cash at close often running 60% to 70% and rollover equity of 25% to 35%. Formal DSO acquisitions in 2026 often price with cash at close of 65% to 75% and rollover equity of 20% to 30%. Platform versus add-on pricing can differ meaningfully, so understanding which buyer tier fits your practice can be helpful before you go to market.
Why McLerran & Associates Is A Focused Sell-Side Advisor For Dental Owners
McLerran & Associates is a dental-only sell-side advisor that has evaluated more than 10,000 practices, completed roughly 2,000 successful practice sales, and closed approximately $2 billion in transaction volume. Its transaction rate of roughly 85% to 90% compares to an industry norm closer to 35% to 40%, which reflects the firm’s process and specialization.
The firm’s CPA-led, diligence-grade EBITDA analysis helps shape the narrative around the owner’s profitability before buyers frame it themselves. Its structured, auction-style bid process, typically 45 to 60 days and generating around ten offers, brings a vetted pool of DSO and private-equity buyers to the table. This competition has historically lifted valuations compared with going to market alone. Poorly run DSOs are screened out and do not reach clients.
McLerran works only on the sell side. The client is always the practice owner. Do-it-yourself sellers, local generalist brokers, multi-vertical advisors, and free-valuation lead-generation firms can leave money on the table through limited buyer exposure, weak underwriting, or a rough estimate that later gets re-traded in diligence. McLerran’s role is to run a process that aims for a durable outcome rather than a fragile headline number.
Owners should consult their own legal, tax, and financial advisors. This article is educational and does not promise a specific financial outcome.
Explore whether your practice is ready for a process with McLerran & Associates.
Frequently Asked Questions
The questions below address common concerns dentists raise when they first explore a DSO affiliation.
How Far In Advance Should I Start Preparing My Practice For A DSO Affiliation?
Many owners start 12 to 24 months before a planned transaction. Staffing and lease normalization often take 12 to 24 months to appear in trailing financials, and buyers underwrite on trailing-twelve-months performance. Marketing and supply normalization often take 6 to 12 months. The least favorable time to receive a first valuation is after signing a letter of intent, because the buyer has already set an anchor and the seller has less leverage.
Is The Multiple Applied To My Collections Or My EBITDA?
DSO buyers typically apply the multiple to adjusted EBITDA. Adjusted EBITDA is normalized cash flow after add-backs. Collections mainly serve as a reasonableness check and as a scale indicator. A practice can show strong collections and still receive a conservative valuation if EBITDA margin is weak, add-backs are unsupported, or owner dependence is high. Two practices with identical collections can produce very different EBITDA figures depending on overhead, owner compensation normalization, and provider mix.
What Is The Single Biggest Metric That Can Compress A DSO Sale Price?
Owner dependence is often the most powerful factor. When the founding dentist generates the large majority of production, buyers model post-close revenue deterioration and may respond by lowering the multiple, shifting value into escrow or earnout, requiring a longer employment commitment, or asking for a larger rollover equity position. The headline enterprise value may look acceptable while the realized cash at close is materially lower. Reducing owner dependence by hiring and seasoning an associate and distributing new-patient exams can be a high-leverage pre-sale action for many practices.
Will Hiring An Associate Lower My Sale Price?
Hiring an associate can often improve the overall outcome. An associate lowers owner dependence but can temporarily compress EBITDA margin because the associate’s compensation is an operating expense before their production fully ramps. The net effect on price depends on whether the multiple expansion from lower transition risk outweighs the near-term margin dip. In many cases, a well-timed associate hire that is visible in trailing 24-month PMS data supports a stronger result, but sequencing still matters.
What Will A DSO’s Quality-Of-Earnings Team Challenge?
The QoE team will often challenge unsupported add-backs, owner compensation normalization, related-party rent, one-time costs that look recurring, and clinical documentation patterns including CDT code compliance. As noted earlier, the vast majority of lower-middle-market dental deals see a post-LOI price adjustment during the QoE audit. The re-trade usually begins after the LOI is signed, when the seller has granted exclusivity and has less negotiating leverage. A defensible EBITDA bridge, built before the process begins and supported by payroll records, invoices, and PMS data, can help reduce this risk.
How Much Of A DSO Deal Is Paid In Equity Rather Than Cash?
Up to roughly 40% of a DSO deal can be paid in equity instead of cash. Equity can be held at the joint-venture level, which typically provides distributions and a higher floor but a lower ceiling, or at the holding-company level, which offers no distributions but a higher potential ceiling if the platform performs well and achieves a future exit. Rollover equity is not cash. Its value depends on future execution, debt levels, governance, dilution, platform performance, and exit timing.
Do DSO Deals And Private-Buyer Deals Price The Same Way?
DSO deals usually price on a multiple of adjusted EBITDA, which replaces owner compensation with a market-rate associate salary before calculating normalized cash flow. Doctor-to-doctor deals are often priced as a percentage of revenue or a multiple of Seller’s Discretionary Earnings (SDE), which adds back the owner-dentist’s full compensation. A higher DSO multiple applied to a lower EBITDA base can sometimes produce a lower dollar outcome than a lower private-buyer multiple applied to a higher SDE base. Because McLerran & Associates works in both paths, the firm can prepare a side-by-side valuation that makes the comparison clearer.
When Should I Delay Or Revisit A Process?
If owner dependence is high, hygiene is under 25% of production, or add-backs are not documented, the practice may be repriced in diligence. In those situations, some owners choose to delay the process by 12 to 18 months to move the metrics first. McLerran & Associates can provide a candid view of how the practice is positioned and can revisit the valuation later if the timing is not yet right.
Conclusion: Move The Metrics Before You Go To Market
DSO sale price typically reflects a multiple applied to adjusted EBITDA, and many of the metrics behind that number can move if you start 12 to 24 months before going to market. Owner dependence, hygiene production, overhead percentage, payer mix, and the defensibility of your add-backs all interact. Focusing on one metric without modeling the net effect on price can create surprises. Practices whose EBITDA is well supported often fare better in the quality-of-earnings process than those that rely only on a high headline number.
McLerran & Associates is a dental-only sell-side advisor that helps owners shape the story around EBITDA, create competition among vetted buyers, and find a fit that aligns with their goals. Owners should consult their own legal, tax, and financial advisors. This article is educational and does not promise a specific financial outcome.
Get a confidential review of your practice’s sale readiness with McLerran & Associates.
